{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Number of subjects with stable or decreased tumor size from baseline assessment to assessment after 6 months of treatment. Radiologic assessment of tumor size before and after treatment will be made by MRI.","groups":[{"description":"Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study\n\nRopinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole","id":"OG000","title":"ROP Intervention"}],"paramType":"NUMBER","populationDescription":"Nine participants analyzed as only 9 participants had a followup MRI at 6 months.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Subjects With Stable or Decreased Tumor Size","type":"SECONDARY","unitOfMeasure":"participants"}